Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774677 | 1.00 | ALDH1A1 (0.42) | ALDH1A1MAOBCYP19A1CALM1TSHR | |
| SCHEMBL6726921 | 0.91 | TACR1 (0.36) | ALDH1A1MAOBCYP19A1CALM1TSHR | |
| SCHEMBL1742765 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CYP19A1CALM1TSHRMAPK1 | |
| SCHEMBL627823 | 0.86 | ALDH1A1 (0.58) | ALDH1A1CYP19A1CALM1TSHRMAPK1 | |
| SCHEMBL467237 | 0.84 | ALDH1A1 (0.55) | ALDH1A1CYP19A1CALM1TSHRMAPK1 | |
| SCHEMBL12044476 | 0.83 | PTGS2 (0.43) | ALDH1A1MAOBCYP19A1CALM1TSHR | |
| SCHEMBL28764954 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MAOBCYP19A1CALM1TSHR | |
| SCHEMBL7672491 | 0.81 | ALDH1A1 (0.40) | ALDH1A1MAOBCYP19A1CALM1MAPK1 | |
| SCHEMBL1362261 | 0.81 | MAOB (0.42) | ALDH1A1MAOBCYP19A1GRIN2DGRIN3B | |
| SCHEMBL587024 | 0.81 | DAO (0.43) | ALDH1A1MAOBCYP19A1CALM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | SHANGHAI MEDICILON INC. (CN) | 2025-09-02 | — | — | US | disclosed |
| EP-4565562-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-11-24 | — | — | US | disclosed |
| US-6943169-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | disclosed |
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| EP-0229510-B1 | SULFINYL AND SULFONYL SUBSTITUTED-3-BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | disclosed |
| CN-86108627-A | The 3-benzazepines that sulfinyl and sulphonyl replace | — | 1987-07-22 | — | — | CN | disclosed |
| US-4659706-A | Sulfinyl and sulfonyl substituted 3-benzazepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | ALDH1A1 1930/4885MAOB 3200/4885CYP19A1 3130/4885 |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | NQO2, UGT1A8, UGT1A1 | ALDH1A1 249/4885MAOB 488/4885CYP19A1 82/4885 |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ALDH1A1 1803/4885MAOB 2000/4885CYP19A1 4131/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | ALDH1A1 1720/4885MAOB 1638/4885CYP19A1 1589/4885 |
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | GIPR, PGC, GRPR | ALDH1A1 625/4885MAOB 2728/4885CYP19A1 2252/4885 |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | PCSK9, LPL, LYPLA1 | ALDH1A1 219/4885MAOB 470/4885CYP19A1 691/4885 |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | RECQL, NQO2, QRFPR | ALDH1A1 803/4885MAOB 578/4885CYP19A1 133/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ALDH1A1 1720/4885MAOB 1638/4885CYP19A1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.